NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00318266|
Recruitment Status : Completed
First Posted : April 26, 2006
Last Update Posted : August 25, 2017
|Condition or disease||Intervention/treatment|
|Bladder Cancer||Device: Nuclear Matrix Protein 22 Urine sample kit|
|Study Type :||Observational|
|Actual Enrollment :||73 participants|
|Official Title:||NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||May 2008|
|patients with suerficial transitional cell carcinoma||
Device: Nuclear Matrix Protein 22 Urine sample kit
Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00318266
|London Health Sciences Centre|
|London, Ontario, Canada, N6A 4G5|
|Principal Investigator:||Jonathan Izawa, MD FRCSC||University of Western Ontario, Canada|